CSL Behring Licenses Phase III Haemophilia B Gene Therapy Candidate from uniQure

By Sasha Yachu & Michelle Liu

Pharma Deals Review: Vol 2020 Issue 7 (Table of Contents)

Published: 29 Jul-2020

DOI: 10.3833/pdr.v2020.i7.2551     ISSN: 1756-7874

Section: Licensing



In a bid to grow its gene therapy footprint, CSL Behring has agreed to acquire the global licensing rights to commercialise uniQure’s Phase III gene therapy programme, AMT-061 (etranacogene dezaparvovec), for the treatment of haemophilia B...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details